@article{fdi:010079419,
  title = {{M}ultiplex detection and dynamics of {I}g{G} antibodies to {SARS}-{C}o{V}2 and the highly pathogenic human coronaviruses {SARS}-{C}o{V} and {MERS}-{C}o{V}},
  author = {{A}youba, {A}hidjo and {T}haurignac, {G}uillaume and {M}orquin, {D}. and {T}uaillon, {E}. and {R}aulino, {R}. and {N}kuba, {A}. and {L}acroix, {A}udrey and {V}idal, {N}icole and {F}oulongne, {V}. and {L}e {M}oing, {V}. and {R}eynes, {J}. and {D}elaporte, {E}. and {P}eeters, {M}artine},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {K}nowledge of the {COVID}-19 epidemic extent and the level of herd immunity is urgently needed to help manage this pandemic. {M}ethods: {W}e used a panel of 167 samples (77 pre-epidemic and 90 {COVID}-19 seroconverters) and {SARS}-{C}o{V}1, {SARS}-{C}o{V}2 and {MERS}-{C}o{V} {S}pike and/or {N}ucleopcapsid ({NC}) proteins to develop a high throughput multiplex screening assay to detect {I}g{G} antibodies in human plasma. {A}ssay performances were determined by {ROC} curves analysis. {A} subset of the {COVID}-19+ samples (n= 36) were also tested by a commercial {NC}-based {ELISA} test and the results compared with those of the novel assay. {R}esults: {O}n samples collected >= 14 days after symptoms onset, the accuracy of the assay is 100 % (95 % {CI}: 100-100) for the {S}pike antigen and 99.9 % (95 % {CI}:99.7-100) for {NC}. {B}y logistic regression, we estimated that 50 % of the patients have seroconverted at 5.7 +/- 1.6; 5.7 +/- 1.8 and 7.9 +/- 1.0 days after symptoms onset against {S}pike, {NC} or both antigens, respectively and all have seroconverted two weeks after symptoms onset. {I}g{G} titration in a subset of samples showed that early phase samples present lower {I}g{G} titers than those from later phase. {I}g{G} to {SARS}-{C}o{V}2 {NC} cross-reacted at 100 % with {SARS}-{C}o{V}1 {NC}. {T}wenty-nine of the 36 (80.5 %) samples tested were positive by the commercial {ELISA} while 31/36 (86.1 %) were positive by the novel assay. {C}onclusions: {O}ur assay is highly sensitive and specific for the detection of {I}g{G} antibodies to {SARS}-{C}o{V}2 proteins, suitable for high throughput epidemiological surveys. {T}he novel assay is more sensitive than a commercial {ELISA}.},
  keywords = {{COVID}-19 ; {SARS}-{C}o{V}2 ; {SARS} ; {L}uminex ; {S}erology ; {FRANCE}},
  booktitle = {},
  journal = {{J}ournal of {C}linical {V}irology},
  volume = {129},
  numero = {},
  pages = {art. 104521 [6p.]},
  ISSN = {1386-6532},
  year = {2020},
  DOI = {10.1016/j.jcv.2020.104521},
  URL = {https://www.documentation.ird.fr/hor/fdi:010079419},
}